About agios pharmaceuticals inc. - AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
AGIO At a Glance
Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge, Massachusetts 02139-4169
| Phone | 1-617-649-8600 | Revenue | 36.50M | |
| Industry | Pharmaceuticals: Major | Net Income | 673.73M | |
| Sector | Health Technology | 2024 Sales Growth | 36.07% | |
| Fiscal Year-end | 12 / 2025 | Employees | 488 | |
| View SEC Filings |
AGIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 2.823 |
| Price to Sales Ratio | 52.119 |
| Price to Book Ratio | 1.219 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.536 |
| Enterprise Value to Sales | 29.194 |
| Total Debt to Enterprise Value | 0.053 |
AGIO Efficiency
| Revenue/Employee | 74,790.984 |
| Income Per Employee | 1,380,584.016 |
| Receivables Turnover | 8.882 |
| Total Asset Turnover | 0.028 |
AGIO Liquidity
| Current Ratio | 11.898 |
| Quick Ratio | 11.558 |
| Cash Ratio | 11.012 |
AGIO Profitability
| Gross Margin | 73.10 |
| Operating Margin | -1,166.467 |
| Pretax Margin | 1,967.146 |
| Net Margin | 1,845.923 |
| Return on Assets | 51.819 |
| Return on Equity | 57.29 |
| Return on Total Capital | 42.162 |
| Return on Invested Capital | 55.017 |
AGIO Capital Structure
| Total Debt to Total Equity | 3.698 |
| Total Debt to Total Capital | 3.566 |
| Total Debt to Total Assets | 3.426 |
| Long-Term Debt to Equity | 2.609 |
| Long-Term Debt to Total Capital | 2.516 |